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Background: During febrile neutropenia in only 30 to 60 percent an infectious agent is identified. This diagnostic
gap could hypothetically be reduced with the broad implementation of molecular detection techniques like PCR,
which has revolutionized the detection of infectious diseases during the last two decades.
Findings: We performed a longitudinal prospective study (N = 81) of neutropenic patients to assess the role of
respiratory viruses in neutropenic fever and to determine the clinical relevance of blind screening for these viruses.
Respiratory viruses were recovered in 14% of the patients prior to neutropenia. In 13% of neutropenic patients
without fever and in 19% of those with fever, a respiratory virus was detected. Comparing different sample types;
nasal swabs performed significantly better (16/117 = 43%), than throat swabs (6/106 = 6%). Throat gurgles did not
show significant differences from the latter sample types.
Conclusions: Blind diagnostic screening for respiratory viruses before or during neutropenia is not useful. Nasal
swabs are sensitive and practical option for screening on respiratory viruses.
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Fever during neutropenia is a frequent problem in patients
with hematological malignancies and is the most common
cause of non-malignant morbidity and mortality in this
patient group [1]. An infectious etiology is identified in
only 30 to 60 percent of the febrile neutropenic episodes
[2-4]. Despite this diagnostic gap, most studies and guide-
lines merely presume bacterial and fungal microorganisms
as the cause of neutropenic fever, but do not extensively
look at possible viral etiologies [2-5]. Since respiratory vi-
ruses are known to be the most common cause of fever in* Correspondence: R.R.Jansen@olvg.nl
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reproduction in any medium, provided the orthe general population and the clinical presentation of a
viral infection is often not specific in neutropenic patients,
diagnostic screening for respiratory viruses seems rational
in patients presenting with neutropenic fever. In children,
there is growing evidence that neutropenic fever is fre-
quently associated with respiratory viral infections [6,7].
Moreover, in stem cell transplantation (SCT) patients, vi-
ruses are recognized to frequently cause post-transplant
fever [8-11].
Over the last decade molecular techniques, such as
polymerase chain reaction (PCR), have revolutionized the
diagnosis of viral infections. PCR has enabled rapid and
highly sensitive detection of a large number of respiratory
viruses, including those that cannot, or are difficult, to
culture, such as human Bocavirus (hBoV) and human
metapneumovirus (HMPV) [12-14]. In patients withLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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sensitive than viral culture [11,15], but these studies have
not looked into viral prevalence during neutropenic fever.
This study was performed to look at the role of respiratory
viruses in neutropenic fever in adults with a hematological
malignancy and assess the usefulness of screening for re-
spiratory viruses before the onset of neutropenia.
Methods
This paper describes a prospective study performed at the
Academic Medical Centre (AMC), which acts as tertiary
referral centre in the Netherlands. Data was obtained by a
longitudinal cohort study at the adult hematology ward
of the AMC and was performed from November 2008
until April 2010. Patients were eligible for inclusion
when chemotherapy-induced significant neutropenia
(i.e. > 7 days) was expected. A patient could be included for
every successive neutropenic episode, assuming that the
latter episode was followed by full recovery of the periph-
eral blood neutrophil count and the patient had been
discharged from the hospital in between episodes. Three
types of respiratory specimens (a nasal swab, pharyngeal
swab and throat gurgle) were collected at 3 different time
points: upon admission (i.e. around the onset of chemo-
therapy), during deep neutropenia (10–14 days after onset
of chemotherapy) and, if present, at the start of neutro-
penic fever. The 3 different time points were labeled as
phase A, phase B and phase C respectively. Fever was
defined as a single temperature of >38.5°C or a sustained
temperature of >38°C for more than one hour. Each
patient’s symptoms and signs during admission were reg-
istered on a case record form. All materials were analyzed
by quantitative real time multiplex PCR covering the
following viruses; influenzavirus A (InfA) and B (InfB),
enterovirus (EV), adenovirus (AdV), respiratory syncytial
virus (RSV), rhinovirus (RV) and human-metapneumovirus
(hMPV), parainfluenzavirus 1–4, human-parechovirus
(hPeV), human-coronavirus (hCoV: HKU1, NL63, 229E
and OC43) and human-bocavirus (hBoV) [16,17]. This
was done at the end of the study; hence treating physi-
cians were not aware of the study results during patient
treatment. The local ethics committee approved the
study and all participating patients provided written in-
formed consent before entering the study.
Results
Patients characteristics and symptomatology
This study prospectively included 66 patients who devel-
oped a total of 81 episodes of neutropenia and 42 epi-
sodes of neutropenic fever during the study. In ten of
these 81 episodes, sampling at the onset of chemother-
apy could not be performed and merely samples during
neutropenia were collected. Of the included 81 neutro-
penic patients (phase A) 42 developed neutropenic fever(phase C). Most of them (n = 35) developed fever before
day 10–14 after onset of chemotherapy, and therefore
passed over sampling at phase B. Patient characteristics
are shown in Table 1. Acute myeloid leukemia was the
most frequent diagnosis, followed by multiple myeloma
and relapsed diffuse large cell non-Hodgkin lymphoma.
Most patients were treated with intensive chemotherapy
or myeloablative chemotherapy followed by autologous
stem cell rescue or by allogeneic stem cell transplant-
ation. A limited number of patients who were treated
with reduced intensity conditioning followed by allogen-
eic stem cell transplantation were included.
Respiratory tract signs or symptoms were defined as
rhinorrhoea, coughing, sneezing, sore throat (except in
the neutropenic phase), dyspnea, and crackles or wheezes
at auscultation. Sore throat during neutropenia was not
considered an infectious respiratory symptom since
this was usually associated with chemotherapy-induced
mucositis. Respiratory tract complaints were present in
21% (15/71) of patients upon admission (phase A), in
13% (6/41) of patients during neutropenia (phase B),
and in 24% (10/42) of patients during neutropenic
fever (phase C). A probable clinical diagnosis for neu-
tropenic fever was established by the treating physician
in 23/42 (55%) of febrile patients. The 3 most prevalent
clinical diagnoses were central venous catheter related
infection 13/42 (31%), neutropenic colitis 3/42 (7%) and
pneumonia 3 (7%). In contrast to clinical diagnosis,
28% (9/32) of the patients with neutropenic fever had
abnormalities on imaging possibly consistent with lower
respiratory tract infections.Microbiological findings
Diagnostic results are shown in Table 2. Before the start of
chemotherapy (phase A), viral nucleic acids were detected
in 14% (10/71) of patients. In 13% (6/46) of neutropenic
patients without fever (group B) and in 19% (8/42) of
those with fever (phase C) a respiratory virus was detected
by PCR. The distribution of viral species found in the dif-
ferent groups is described in Table 2. RV was the most
frequently detected virus followed by hBoV and hCoV.
InfA & B and PIV 2 & 4 were not present in any of the
tested samples. No substantial differences in the distri-
bution of specific viral species were observed between
groups. Viral positivity did not show any seasonal pattern
for any of the groups. Patients with respiratory symptoms
were not associated with a higher prevalence of respira-
tory viruses compared to asymptomatic patients. (resp.
2/10 [20%] vs. 6/32 [19%]).
Looking at different sample types, nasal swabs had a
positivity rate of 14% (16/117), compared to 6% (6/106)
for throat swabs and 9% (14/148) for throat gurgles. The
difference between nasal swabs and throat swabs was
Table 1 Patient characteristics
Group A Group B Group C
Number of neutropenic
episodes
N = 81 N = 46 N = 42
No individual patients 66 41 38
Age (IQR5) 57 (49–64) 56 (38–64) 59 (50–65)
Sex female (%) 34 (42%) 14 (30%) 24 (57%)
Hematological disorder:
AML (%) 36 (44%) 17 (37%) 23 (55%)
CML (%) 3 (4%) 1 (2%) 2 (5%)
ALL (%) 8 (10%) 8 (17%) 1 (2%)
CLL (%) 3 (4%) 3 (7%) 0
HL (%) 2 (2%) 0 2 (5%)
NHL (%) 11 (14%) 7 (15%) 4 (10%)
MM (%) 14 (17%) 9 (18%) 7 (17%)
Other (%) 4 (5%) 2 (4%) 3 (7%)
Treatment type:
Chemotherapy (%) - 29 (63%) 29 (69%)
AutoSCT (%) - 11 (24%) 12 (29%)
AlloSCT r.i. (%) - 2 (4%) 1 (2%)
AlloSCT m.a. (%) - 4 (9%) 1 (2%)
T cell reducing medicine (%) - 3 (6%) 3 (7%)
Explicit Mucositis (%) - 24 (52%) 25 (60%)
Duration of neutropenia
at sampling (IQR5)
- 6 (5–8) 8 (3–12)
COPD (%) 1 (1%) 1 (2%) 0
Smoking (%) 7 (9%) 4 (9%) 3 (7%)
URTSa (%) 15/716 (21%) 6 (13%) 9 (24%)
LRTSb 0 0 1 (2%)
Pulmonary aberration’s
on imagery (%)
- 2 (4%) 10/32c (31%)
Probable Aspergillosis (%) - 0 3 (7%)
Positive Blood cultures (%) - - 12d (29%)
Group A; Baseline population at onset of chemotherapy, Group B; Patients
with deep neutropenia, without fever, Group C; Patients with deep
neutropenia and fever . IQR Inter quartile range, AML Acute myeloid leukemia,
CML Chronic myeloid leukemia, ALL Acute lymphoblastic leukemia, CLL
Chronic lymphoblastic leukemia, HL Hodgkin lymphoma, NHL Non Hodgkin
lymphoma. AutoSCT Autologous stem cell transplantation, AlloSCT r.t.
Allogeneic stem cell transplantation reduced intensity, regimen, AlloSCT m.a.
Allogeneic stem cell transplantation myeloablative regimen. RTS respiratory
tract symptoms.
a URTS Upper respiratory tract symptoms (i.e. rhinitis, sneezing, ear/nose congestions).
b LRTS Lower respiratory tract symptoms (i.e. dyspnea, or coughing in
combination with auscultation of the lung suggesting bronchitis/pneumonia,
or coughing in combination with abnormalities on lung imagery, suspected
for infection.
c Respiratory imaging was performed in 32 of the patients.
d Eleven of 12 bloodcultures contained bacteria normally found on the skin
(mainly coagulase-negative staphylococcae); in most of the cases this was
interpreted by the clinician as a possible central venous catheter infection.
Table 2 PCR results in relation to patient characteristics
Phase A Phase B Phase C
N = 71 N = 46 N = 42
Viral positivity (percentage) 10/71 (14%) 6 (13%) 8 (19%)
Viral positivity in persons:
with URTS 1/15 (7%) 1/6 (16%) 1/9 (11%)
with LRTS 0 0 1/1 (100%)
without RTS 9/56 (16%) 5/40 (13%) 6/32 (19%)
Viral positivity in persons:
with suspected imagerya - - 1/109 (10%)
without suspected imagerya - - 4/229 (18%)
Nasal swab Positive (%) 6/57 (11%) 5/35 (14%) 5/25 (20%)
Pharyngeal swab Positive (%) 2/51 (4%) 2/33 (6%) 2/22 (9%)
Throat gurgle positive (%) 5/71 (7%) 4/42 (10%) 5/35(14%)
Frequencies of detect
viral species:
RV 4 (6%) 1 (4%) 3 (7%)
RSV 1 (1%) 1(4%) 0
hMPV 0 0 1 (2%)
hBoV 2 (3%) 0 2 (4%)
PeV 1 0 0
AdV 1 0 1 (2%)
hCoV 1 2 (8%) 1 (2%)
PIV2 0 2 0
PIV3 0 1 (4%) 0
Phase A; Baseline population at onset of chemotherapy, notice that ten
patients could not be sampled before the start of chemotherapy (N = 71),
Phase B; Patients with deep neutropenia, without fever, Phase C; Prospective
patients with deep neutropenia and fever. URTS upper respiratory tract
symptoms, LRTS lower respiratory tract symptoms, RTS respiratory tract
symptoms, RV rhinovirus, RSV respiratory syncytial virus, hMPV human
metapneumovirus, HBoV human bocavirus, PeV parechovirus, AdV adenovirus,
hCoV corona virus, PIV 2&3 para-influenza virus 1,2,3,4. CP-value crossing point
value, IQR inter quartile range.
a x-ray or CT-scan of the thorax.
b The following viuses were not detected: Inf A/B; influenza viruses A and B,
EV; enterovirus, para-influenza virus 1&4.
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multiple samples were taken, more than one sample was
positive in 49% of the paired samples.Longitudinal analyses of prospective samples showed that
of the 10 viruses found before the start of chemotherapy
only 2 were still present during neutropenia (one in a patient
with, and another in a patient without, neutropenic fever).
In both cases it concerned RV.
Discussion
Clinical management of neutropenic fever remains a chal-
lenge during the treatment of hematological malignancies.
In these patients, symptoms are often non-specific and an
etiology of infection is frequently not established. In the
present study, we performed a longitudinal prospective
study to address the role of respiratory viruses in causing
neutropenic fever and to assess the clinical relevance of
diagnostic screening for respiratory viruses during the
course of neutropenia.
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prominent etiological role of respiratory viruses in the
development of neutropenic fever. Patients in whom
respiratory viruses were detected did not exhibit more
respiratory symptoms or signs than patients without re-
spiratory viruses. While this could possibly be explained
by altered or non-specific symptomatology in an immuno-
compromised setting, there also were no differences in the
frequency of virus detection in respiratory specimens
obtained before and during neutropenia and during
episodes of neutropenic fever. Moreover, respiratory
viruses that were present in specimens obtained before
the onset of neutropenia seldom remained detectable in
follow up specimens collected during neutropenia. These
observations suggest that elaborate diagnostic screening
for respiratory viruses before or during (febrile) neu-
tropenia is not clinically useful. However it should be
noted that the virus species detected in our samples were
mostly species that are considered to be less pathogenic
(e.g. RV, hBoV and hCoV). For example, Inf A was rarely
found. The latter fact could partly be explained by an
increased awareness and reinforcement of preventive
measures during the threat of the newly appeared H1N1
influenza strain in 2009.
Considering the type of sampling, we observed that
nasal swabs performed better than throat swabs. To our
knowledge, only a few studies have compared nasal swaps
to other sampling techniques when testing for respiratory
virus by PCR in adults, and none have been performed in
adults with hematological malignancies. These studies
showed superior performance for nasal swabs compared
to pharyngeal swabs [18,19], although, the use of two
simultaneous techniques resulted in the highest yield of
positive results. Our findings support the latter findings
and suggest that the sole use of pharyngeal swabs should
be avoided for viral detection in hematological patients.
As shown in Table 2, a complete set of nasal swab,
pharyngeal swab and throat gurgle was not obtained for
all patients, which could possibly introduce a bias when
comparing sampling methods. However since every sam-
ple was obtained simultaneously with at least one other
sample we think this bias is small.
Although routine screening for respiratory is not war-
ranted, in subject with respiratory symptoms viral testing is
useful to determine the etiology for the complaints, the
start of barrier precautions and the start of adequate treat-
ment in the case of influenza. In these patients testing of
lower respiratory tract samples is favorable to upper re-
spiratory samples [20,21]. Our study had the following limi-
tations; our study is performed in a relatively small study
group and represents only limited time span. The circula-
tion and the pathogenicity of viruses can differ from year,
and therefore the findings in our study cannot be directly
extrapolated to future viral respiratory seasons in otherclinical settings. A second limitations is that because of the
rise of the new pandemic H1N1 in 2009, there was much
more awareness for preventive measures around respiratory
virus (i.e. hand hygiene on the ward and vaccination among
staff and general population) which may have reduced
the spread of influenza and other respiratory virus on
our hematology ward.
In conclusion, our prospective study does not support
the hypothesis that respiratory viruses play an important
role in the development of neutropenic fever, and thus
screening for respiratory virus before or during neutro-
penia is not useful.
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